Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orit Bar Am

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Pharmacology|April 3, 2012
Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidaseOrit Bar-Am, Aviva Gross, Rachel Friedman, et al.
Progress in Neurobiology|July 31, 2007
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agentsSilvia Mandel, Tamar Amit, Orit Bar-Am, et al.
Journal of Molecular Neuroscience : MN|August 30, 2008
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged ratsOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Progress in Neurobiology|July 6, 2010
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activityOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2005
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Journal of Neurochemistry|December 17, 2009
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagilineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 4, 2003
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processingMerav Yogev-Falach, Tamar Amit, Orit Bar-Am, et al.
Antioxidants & Redox Signaling|October 6, 2010
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?Orly Weinreb, Orit Bar-Am, Ksenia Prosolovich, et al.
Molecular Neurobiology|August 1, 2012
Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in miceLana Kupershmidt, Tamar Amit, Orit Bar-Am, et al.
Journal of Neurochemistry|August 8, 2007
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseasesLana Kupershmidt, Tamar Amit, Orit Bar-Am, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Pharmacology|April 3, 2012
Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidaseOrit Bar-Am, Aviva Gross, Rachel Friedman, et al.
Progress in Neurobiology|July 31, 2007
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agentsSilvia Mandel, Tamar Amit, Orit Bar-Am, et al.
Journal of Molecular Neuroscience : MN|August 30, 2008
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged ratsOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Progress in Neurobiology|July 6, 2010
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activityOrly Weinreb, Tamar Amit, Orit Bar-Am, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2005
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
Journal of Neurochemistry|December 17, 2009
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagilineOrit Bar-Am, Orly Weinreb, Tamar Amit, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 4, 2003
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processingMerav Yogev-Falach, Tamar Amit, Orit Bar-Am, et al.
Antioxidants & Redox Signaling|October 6, 2010
Does 1-(R)-aminoindan possess neuroprotective properties against experimental Parkinson's disease?Orly Weinreb, Orit Bar-Am, Ksenia Prosolovich, et al.
Molecular Neurobiology|August 1, 2012
Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in miceLana Kupershmidt, Tamar Amit, Orit Bar-Am, et al.
Journal of Neurochemistry|August 8, 2007
The neuroprotective effect of Activin A and B: implication for neurodegenerative diseasesLana Kupershmidt, Tamar Amit, Orit Bar-Am, et al.
Pageof 7